Inclusion Criteria:  Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association) Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review & Assessment Service insurance coverage treatment criteria*) for whom drug treatment with pravastatin is confirmed Participants determined to be eligible as subjects at the discretion of the investigator Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information  Exclusion Criteria:  Participants who had administered pravastatin prior to study participation Participants with hypersensitivity to the investigational product or its history Participants with an active liver disease or persistent elevation of transaminase with an unknown cause Pregnant woman or women with childbearing potential, breastfeeding mothers Children Participants with severe hepatic or renal insufficiency Participants with myopathy Participants with cholestasis Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption